Generation Bio Co. (GBIO)
NASDAQ: GBIO · Real-Time Price · USD
4.200
-0.130 (-3.00%)
Jul 24, 2025, 4:00 PM - Market closed

Company Description

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.

It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity.

The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.

Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Generation Bio Co.
Generation Bio Co. logo
CountryUnited States
Founded2016
IPO DateJun 12, 2020
IndustryBiotechnology
SectorHealthcare
Employees115
CEOCameron McDonough

Contact Details

Address:
301 Binney Street
Cambridge, Massachusetts 02142
United States
Phone617 655 7500
Websitegenerationbio.com

Stock Details

Ticker SymbolGBIO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$19.00
CIK Code0001733294
CUSIP Number37148K100
ISIN NumberUS37148K1007
Employer ID81-4301281
SIC Code2834

Key Executives

NamePosition
Dr. Cameron Geoffrey McDonough M.D.President, Chief Executive Officer and Director
Antoinette Paone M.B.A., M.S.Chief Operating Officer
Dr. Phillip Samayoa Ph.D.Chief Scientific Officer
Dr. Mark D. Angelino Ph.D.Co-Founder
Dr. Robert Kotin Ph.D.Co-Founder
Kevin John ConwayChief Financial Officer
Yalonda Howze J.D.Chief Legal Officer and Secretary
Jasmin TowerChief Human Resources Officer
Caitlin Cooper M.B.A.Senior Vice President and Head of Business Development

Latest SEC Filings

DateTypeTitle
Jul 18, 20258-KCurrent Report
Jul 17, 2025SCHEDULE 13G/AFiling
Jun 5, 20258-KCurrent Report
May 7, 2025S-8Securities to be offered to employees in employee benefit plans
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
Apr 23, 2025ARSFiling
Apr 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2025DEF 14AOther definitive proxy statements
Apr 11, 2025PRE 14AOther preliminary proxy statements